Cue Biopharma (FRA:1UC0) ROCE %: -79.86% (As of Mar. 2026)


FRA:1UC0 Cue Biopharma Inc FRA:1UC0
57 GF Score
Price €25.92
GF Value €51.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma ROCE %?

Cue Biopharma FRA:1UC0 57 ROCE % is -79.86% as of Mar. 2026. GuruFocus rates FRA:1UC0 with a GF Score™ of 57/100 and a GF Value™ of €51.06 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cue Biopharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -79.86%.

Cue Biopharma  (FRA:1UC0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cue Biopharma ROCE % Related Terms

Cue Biopharma ROCE % Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma ROCE % Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.04 -71.67 -78.22 -130.36 -104.21

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -375.25 -235.50 -155.42 38.14 -79.86
FRA:1UC0
57GF Score
Cue Biopharma Inc FRA:1UC0
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma ROCE % Calculation

Cue Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-21.986/( ( (30.742 - 13.073) + (36.049 - 11.524) )/ 2 )
=-21.986/( (17.669+24.525)/ 2 )
=-21.986/21.097
=-104.21 %

Cue Biopharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-17.904/( ( (36.049 - 11.524) + (26.709 - 6.393) )/ 2 )
=-17.904/( ( 24.525 + 20.316 )/ 2 )
=-17.904/22.4205
=-79.86 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -79.86% mean?
Cue Biopharma (FRA:1UC0) has a ROCE % of -79.86% as of Mar. 2026.
Is Cue Biopharma's ROCE % too high?
Cue Biopharma's current ROCE % is -79.86%. Overall, Cue Biopharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's ROCE % compare to TELO and ACET?
Cue Biopharma's ROCE % of -79.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Cue Biopharma's current ROCE % is -79.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (FRA:1UC0) is currently considered Possible Value Trap. The stock's GF Value™ is €51.06, compared to a current price of €25.92 — trading 49.2% below its estimated fair value. The current ROCE % is -79.86%. Cue Biopharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cue Biopharma (FRA:1UC0), the current ROCE % is -79.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (FRA:1UC0) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of €25.92 is trading 49.2% below its estimated GF Value™ of €51.06. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for FRA:1UC0:

  • ROCE %: -79.86%
  • GF Value™: €51.06 vs. price of €25.92 (49.2% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the FRA:1UC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges CUE:USA
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
57GF Score

Get the complete analysis for FRA:1UC0

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.92
Price
€51.06
GF Value